These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22941910)

  • 1. Current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review.
    Maas C; Kane MA; Bucay VW; Allen S; Applebaum DJ; Baumann L; Cox SE; Few JW; Joseph JH; Lorenc ZP; Moradi A; Nestor MS; Schlessinger J; Wortzman M; Lawrence I; Lin X; Nelson D
    Aesthet Surg J; 2012 Sep; 32(1 Suppl):8S-29S. PubMed ID: 22941910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice.
    Carruthers J; Fournier N; Kerscher M; Ruiz-Avila J; Trindade de Almeida AR; Kaeuper G
    Dermatol Surg; 2013 Mar; 39(3 Pt 2):510-25. PubMed ID: 23458295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to: current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review.
    Casas LA
    Aesthet Surg J; 2012 Sep; 32(1 Suppl):7S. PubMed ID: 22941909
    [No Abstract]   [Full Text] [Related]  

  • 5. Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications.
    Sundaram H; Signorini M; Liew S; Trindade de Almeida AR; Wu Y; Vieira Braz A; Fagien S; Goodman GJ; Monheit G; Raspaldo H;
    Plast Reconstr Surg; 2016 Mar; 137(3):518e-529e. PubMed ID: 26910696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review.
    Cohen JL; Scuderi N
    Aesthet Surg J; 2017 May; 37(suppl_1):S32-S44. PubMed ID: 28388721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Uses of AbobotulinumtoxinA in Aesthetics.
    Schlessinger J; Gilbert E; Cohen JL; Kaufman J
    Aesthet Surg J; 2017 May; 37(suppl_1):S45-S58. PubMed ID: 28388720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
    Matarasso A; Shafer D
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin in Aesthetic Medicine: Myths and Realities.
    Dover JS; Monheit G; Greener M; Pickett A
    Dermatol Surg; 2018 Feb; 44(2):249-260. PubMed ID: 29016535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications.
    Rzany B; Fratila AA; Fischer TC; Hilton S; Pavicic T; Rothhaar A; Sattler G; Sommer B; Pickett A
    J Drugs Dermatol; 2013 Jan; 12(1):80-4. PubMed ID: 23377332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.
    Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1278-84. PubMed ID: 20337830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact.
    Jandhyala R
    J Plast Reconstr Aesthet Surg; 2012 Jun; 65(6):720-31. PubMed ID: 22225675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of facial cosmetic botulinum toxin A injection: analysis of the UK Medicines & Healthcare Products Regulatory Agency registry and literature review.
    Zargaran D; Zoller FE; Zargaran A; Mosahebi A
    J Plast Reconstr Aesthet Surg; 2022 Jan; 75(1):392-401. PubMed ID: 34456155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.
    Vlata Z; Tsatsakis A; Tzagournissakis M; Krambovitis E
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):268-73. PubMed ID: 22385115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
    Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
    Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.
    Nestor M; Ablon G; Pickett A
    Aesthet Surg J; 2017 May; 37(suppl_1):S20-S31. PubMed ID: 28388717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest.
    Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1285-95. PubMed ID: 20569284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.